Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
Eur Neuropsychopharmacol June 5, 2026 Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter et al.
No Summary